• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清胆固醇水平未得到充分评估和治疗。

Serum cholesterol levels are underevaluated and undertreated.

作者信息

Danias P G, O'Mahony S, Radford M J, Korman L, Silverman D I

机构信息

Cardiology Division, University of Connecticut Health Center, Farmington 06030-1305, USA.

出版信息

Am J Cardiol. 1998 Jun 1;81(11):1353-6. doi: 10.1016/s0002-9149(98)00167-2.

DOI:10.1016/s0002-9149(98)00167-2
PMID:9631975
Abstract

We reviewed data from 147 patients followed at a Veterans Administration hospital regarding management of hypercholesterolemia. Less than one half of patients with lipid analysis who met Adult Treatment Panel II/National Education Cholesterol Program guideline criteria for initiation of medical therapy received lipid-lowering agents in 1 year of follow-up.

摘要

我们回顾了一家退伍军人管理局医院对147名高胆固醇血症患者的随访数据。在接受血脂分析的患者中,符合成人治疗小组II/国家胆固醇教育计划启动药物治疗指南标准的患者,在1年随访期内接受降脂药物治疗的不到一半。

相似文献

1
Serum cholesterol levels are underevaluated and undertreated.血清胆固醇水平未得到充分评估和治疗。
Am J Cardiol. 1998 Jun 1;81(11):1353-6. doi: 10.1016/s0002-9149(98)00167-2.
2
Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines.根据美国国家胆固醇教育计划指南,冠状动脉钙化进展与血脂控制的关系。
Am J Cardiol. 2004 Aug 15;94(4):431-6. doi: 10.1016/j.amjcard.2004.05.003.
3
United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
Am J Cardiol. 2001 Oct 11;88(7B):23J-27J. doi: 10.1016/s0002-9149(01)01931-2.
4
Lipid management with statins. The lower the better?使用他汀类药物进行血脂管理。越低越好?
Z Kardiol. 2004 Jan;93(1):4-9. doi: 10.1007/s00392-004-1023-y.
5
[Lipid lowering after percutaneous coronary intervention. Intended and achieved treatment goals in real life].
Med Klin (Munich). 2005 Dec 15;100(12):781-4. doi: 10.1007/s00063-005-1108-z.
6
[New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].[高剂量他汀类药物和贝特类药物的新研究。降脂治疗正在如何改变?(医学博士德克·艾内克访谈)]
MMW Fortschr Med. 2005 Dec 8;147(49-50):20.
7
Case reports illustrate consequences of ATP III in practice.
Am J Manag Care. 2003 Aug;Suppl:5-6.
8
LDL-Cholesterol is the King.低密度脂蛋白胆固醇是关键。
Angiology. 2009 Jun-Jul;60(3):387-8. doi: 10.1177/0003319709334121. Epub 2009 Jun 3.
9
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?一级预防中降脂药物治疗的适用标准:成人治疗小组第二次报告和第三次报告指南的比较情况如何?
Circulation. 2002 Jan 15;105(2):136-9.
10
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?
Ann Intern Med. 2000 Oct 3;133(7):549-54. doi: 10.7326/0003-4819-133-7-200010030-00015.

引用本文的文献

1
Undertreatment of hypercholesterolaemia: a population-based study.高胆固醇血症治疗不足:一项基于人群的研究。
Br J Clin Pharmacol. 2003 Apr;55(4):389-97. doi: 10.1046/j.1365-2125.2003.01769.x.
2
[Coronary risk and prescription in primary care patients with hypercholesterolemia].[原发性高胆固醇血症初级保健患者的冠状动脉风险与处方]
Aten Primaria. 2000 Mar 15;25(4):209-13. doi: 10.1016/s0212-6567(00)78488-5.